Brief: Keros Therapeutics Says Durable Clinical Responses Associated With Improvements In Patient-Reported Measures Of Fatigue

Keros Therapeutics

11/12/2023 11:20

Dec 11 (Reuters) - Keros Therapeutics Inc  KROS.O :
    * KEROS THERAPEUTICS INC - DURABLE CLINICAL RESPONSES WERE
ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED MEASURES OF
FATIGUE
    * KEROS THERAPEUTICS INC - KER-050 (ELRITERCEPT) ACHIEVED
DURABLE
TRANSFUSION INDEPENDENCE IN LOWER-RISK MDS
    * KEROS THERAPEUTICS INC - BIOMARKER DATA DEMONSTRATE THAT
KER-050
TREATMENT HAS POTENTIAL TO REDUCE NT-PROBNP A MEASURE OF CARDIAC
STRESS

Source text for Eikon:  ID:nGNX56QLSj 
Further company coverage:  KROS.O